Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
about
Management of bleeding and coagulopathy following major trauma: an updated European guideline.Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaHuman recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseasesRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophiliaHaemostatic drug therapies for acute primary intracerebral haemorrhageHuman recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseasesNew trends in resuscitationDiffuse alveolar hemorrhage and recombinant factor VIIa treatment in pediatric patientsRational Use of Recombinant Factor VIIa in Clinical PracticeThe European guideline on management of major bleeding and coagulopathy following trauma: fourth editionThe Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII.Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data?Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding.Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage.Understanding the therapeutic action of recombinant factor VIIa in platelet disorders.[Therapy with blood products].Use of recombinant factor VIIa in uncontrolled gastrointestinal bleeding after hematopoietic stem cell transplantation among patients with thrombocytopeniaProthrombin Complex Concentrates for Bleeding in the Perioperative Setting.Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital recordsPolyphosphate as a general procoagulant agent.The role of tissue factor and factor VIIa in hemostasis.Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation.Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indicationsThe hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?Recombinant activated factor VII in controlling bleeding in non-hemophiliac patientsManagement of bleeding following major trauma: an updated European guideline.Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patientsRecombinant factor VII is associated with worse survival in complex cardiac surgical patientsCombination use of platelets and recombinant activated factor VII for increased hemostasis during acute type a dissection operations.Recombinant activated factor VIIa treatment for refractory hemorrhage in infants.Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysisAssociation of coagulation-related and inflammation-related genes and factor VIIc levels with stroke: the Cardiovascular Health StudyRecombinant factor VIIa is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patientsBlood transfusion practices in obstetric anaesthesia.Single center experience on dosing and adverse events of recombinant factor seven use for bleeding after congenital heart surgery.Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study.Risk of thromboembolism following acute intracerebral hemorrhageThe Effect of Intravenous Administration of Active Recombinant Factor VII on Postoperative Bleeding in Cardiac Valve Reoperations; A Randomized Clinical Trial.Utilization management in the blood transfusion service
P2860
Q21092902-3A80DDE0-D9D5-47C6-9469-4B208810BE95Q24201292-794648ED-A168-4C84-994A-05EAF2CE35EDQ24201303-D256205E-4D49-409C-B092-DF2605412CB5Q24236583-E0005A88-0323-4416-93EB-86B8671841ADQ24245204-5C3AAB6F-A8AE-4EDA-8738-D3BB8DDB1956Q24245531-CEA1037D-2416-4F5E-A65B-EB8998A7E0EBQ24246238-F4E320FD-CEB2-4DB5-94B1-2C0B6E56DDFAQ24599047-1D836B14-947D-4906-8C4C-12D75264A86AQ26749256-5849F3DA-046C-432B-B5B9-61184FF8FDADQ26829915-5EEFBFD2-7EE4-43D6-BFA4-7F18C800A059Q27339343-2C3C15F2-C762-4C57-99CF-E9D7964E5CC9Q30833127-05FBDCD8-CA73-4BB6-889E-928FE65D03E9Q31040247-FB882CE8-CDB0-42E5-A1A3-478D70FFDBD2Q33282917-A1066B49-5A70-470D-9543-87E06E2C6405Q33335930-12704FFB-C7AB-4CD4-992A-62414BCF8C13Q33382014-4FBD98A2-0852-4D23-8E30-1340B2AE94FEQ33429614-F25D466E-FD4F-4C89-8147-6706910B2EABQ33429950-7EF3AC42-61C9-4816-BF8F-1F8B29C60C95Q33430766-FE92D51F-CABB-4AE7-9C8D-FCC85A3EE24DQ33571590-21BAB7DB-B1CC-4C2F-88D9-36F167F29E0BQ33724794-5B849D15-02EC-47FA-B96F-B34DCADD6A8EQ33728350-86EBC003-842F-458E-A38F-3A539EA7881DQ33756657-5AD2B458-B96C-4E71-800D-3A209F5DAAE7Q33876266-D721500F-C48E-46FF-8B73-AE788F6A534EQ33911771-7C7DB429-C50A-4880-9AB0-1A86AD07F229Q33918017-A3363400-0F88-4CC6-944C-8816725F100EQ33919178-8ACEFF46-F61D-4ECD-A5BD-95436DC9FC96Q33959616-9DF6857D-FAF4-4D4E-9D96-836F816063EDQ34005911-03019713-DE88-4833-8F6D-AB4D2A1F9EC5Q34143840-D1444E14-D0FF-4F95-B4DB-3F6A0606DAE0Q34274196-2B65693D-4B2C-4BBD-ADDA-75BEA1BB5A02Q34472516-954F9450-9FDD-41A2-B3EA-B9D142E4CA71Q34538431-204FB2B5-1E52-48BC-ADDD-014F5829E57EQ34604004-4FBFA937-9BB8-4F96-A5D1-2DE0C8DDFDC6Q34659811-572A1129-DF8D-4C88-ACA8-CDD681D163A0Q34759669-5B607721-651B-4F2D-A4C7-78926A2227C1Q34786006-93C02549-62F2-4E72-B64C-D22130D7AE84Q35018742-6A6BE056-3DFA-40F6-A576-B2B2C06EF911Q35148987-D5B1118D-C8B9-49B9-A52C-647624E15583Q35492937-6F684A4F-3354-4C54-A64C-0518599E94B0
P2860
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
@ast
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
@en
type
label
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
@ast
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
@en
prefLabel
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
@ast
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
@en
P2093
P356
P1476
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.
@en
P2093
Jay N Lozier
Jennifer J Wood
Kathryn A O'Connell
M Miles Braun
Robert P Wise
P304
P356
10.1001/JAMA.295.3.293
P407
P577
2006-01-01T00:00:00Z